Plasma clozapine concentration coefficients of variation in a long-term study

Schizophrenia Research

Volumn 72, Issue 2-3, 2005, Pages 131-135

  Diaz, Francisco J ^a   De Leon, Jose ^b   Josiassen, Richard C ^c   Cooper, Thomas B ^d   Simpson, George M ^e  

^a UNIVERSIDAD NACIONAL DE COLOMBIA   (Colombia)

^b Mental Health Research Center   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Clozapine; Pharmacokinetics; Plasma clozapine concentrations

Indexed keywords

CAFFEINE; CLOZAPINE; NORCLOZAPINE;

ADULT; ARTICLE; BEVERAGE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; FEMALE; HEMOCONCENTRATION; HUMAN; MALE; MEASUREMENT; MENTAL PATIENT; METHODOLOGY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SMOKING;

ADULT; ANTIPSYCHOTIC AGENTS; CLOZAPINE; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; SCHIZOPHRENIA; SEVERITY OF ILLNESS INDEX; SMOKING; TIME FACTORS;

EID: 9244244152     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.schres.2004.03.017     Document Type: Article

References (13)

1. Bertilsson L., Carrillo J.A., Dahl M.L., Llerena A., Alm C., Bondesson U., Lindstrom L., de la Rubia I., Ramos S., Benitez J. Clozapine disposition covaries with CYP1A2 activity determined by a caffeine test. Br. J. Clin. Pharmacol. 38:1994;471-473
2. Bertz R.J., Granneman G.R. Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clin. Pharmacokinet. 32:1997;210-258
3. de Leon J. Glucuronidation enzyme genes and psychiatry. Int. J. Neuropsychopharmacol. 6:2003;57-72
4. de Leon, J., in press. Respiratory infections rather than antibiotics may increase clozapine levels: A critical review of the literature (letter). J. Clin. Psychiatry.
5. de Leon J., Diaz F.J. Serious respiratory infections can increase clozapine levels and contribute to side effects: a case report. Prog. Neuro-Psychopharmacol. Biol. Psychiatry. 27:2003;1059-1063
6. de Leon J., Dadvand M., Canuso C., White A.O., Stanilla J.K., Simpson G.M. Schizophrenia and smoking: an epidemiological survey in a state hospital. Am. J. Psychiatry. 152:1995;453-455
7. Kane J.M., Honigfeld G., Singer J., Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch. Gen. Psychiatry. 45:1988;789-796
8. Kurz M., Hummer M., Kemmler G., Kurzthaler I., Saria A., Fleischhacker W.W. Long-term pharmacokinetics of clozapine. Br. J. Psychiatry. 173:1998;341-344
9. Ozdemir V., Kalow W., Posner P., Collins E.J., Kennedy J.L., Tang B., Albers L.J., Reist C., Roy R., Walkes W., Afra P. CYP1A2 activity as measured by a caffeine test predicts clozapine and active metabolite norclozapine steady-state concentration in patients with schizophrenia. J. Clin. Psychopharmacol. 21:2002;398-407
10. Pinninti N.R., de Leon J. Interaction of sertraline with clozapine (letter). J. Clin. Psychopharmacol. 17:1997;119-120
11. Simpson G.M., Cooper T.A. Clozapine plasma levels and convulsions. Am. J. Psychiatry. 135:1978;99-100
12. Simpson G.M., Josiassen R.C., Stanilla J.K., de Leon J., Nair C., Abraham G., Odom-White A., Turner R.M. Double-blind study of clozapine dose response in chronic schizophrenia. Am. J. Psychiatry. 156:1999;1744-1750
13. SPSS Inc, 1997. SPSS Advanced Statistics 7.5. SPSS, Chicago.